124 related articles for article (PubMed ID: 6896795)
21. M-AMSA in disseminated prostatic carcinoma: a phase II study.
Drelichman A; Decker DA; Al-Sarraf M; Dhabuwala CB
Cancer Treat Rep; 1982 Nov; 66(11):1993-4. PubMed ID: 6897206
[No Abstract] [Full Text] [Related]
22. Phase II trial of (m-AMSA) 4'-9-(acridinylamino)-methanesulfon-m-aniside in primary liver cancer.
Cheng E; Lightdale C; Young C; Yagoda A; Fortner J; Golbey R
Am J Clin Oncol; 1983 Apr; 6(2):211-3. PubMed ID: 6299095
[No Abstract] [Full Text] [Related]
23. Phase II trial of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study.
Al-Sarraf M; Frank J; Smith JA; O'Bryan RM; Costanzi JJ; Stephens RL; Caraveo J; Crawford ED
Cancer Treat Rep; 1985 Feb; 69(2):189-94. PubMed ID: 2578880
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of amsacrine (AMSA) in urinary bladder cancer.
Natale RB; Yagoda A; Blumenreich MS; Watson RC
Cancer Treat Rep; 1983 Apr; 67(4):391-2. PubMed ID: 6687836
[No Abstract] [Full Text] [Related]
25. Phase II evaluation of m-AMSA (4'-(9-acridinylamino)-methanesulfon-m-anisidide) in patients with adenocarcinoma of the pancreas.
Sternberg CN; Magill GB; Sordillo PP; Cheng E; Currie VE
Am J Clin Oncol; 1983 Aug; 6(4):459-62. PubMed ID: 6688151
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinoma.
Van Echo DA; Markus S; Aisner J; Wiernik PH
Cancer Treat Rep; 1980; 64(8-9):1009-10. PubMed ID: 6893810
[No Abstract] [Full Text] [Related]
27. Phase I study of m-AMSA in patients with solid tumors and leukemias.
Goldsmith MA; Bhardwaj S; Ohnuma T; Greenspan EM; Holland JF
Cancer Clin Trials; 1980; 3(3):197-202. PubMed ID: 6893683
[TBL] [Abstract][Full Text] [Related]
28. Phase I-II study of m-AMSA administered as a continuous infusion.
Micetich KC; Zwelling LA; Gormley P; Young RC
Cancer Treat Rep; 1982 Oct; 66(10):1813-7. PubMed ID: 6897013
[TBL] [Abstract][Full Text] [Related]
29. m-AMSA in refractory lymphoma. A phase II trial of the Eastern Cooperative Oncology Group.
Keller AM; Tsiatis AA; Neiman RS; Glick JH; Mann RB
Am J Clin Oncol; 1985 Oct; 8(5):449-52. PubMed ID: 3840644
[TBL] [Abstract][Full Text] [Related]
30. Amsacrine (m-AMSA) in squamous cell carcinoma of the uterine cervix: a Southwest Oncology Group study.
Hilgers RD; Legha SS; Boutselis JG; Hannigan EV; Stephens RL; Tranum BL; Surwit E
Cancer Treat Rep; 1984 Feb; 68(2):443-4. PubMed ID: 6546533
[No Abstract] [Full Text] [Related]
31. Phase II study of amsacrine in refractory lymphomas. A report of the EORTC Early Clinical Trials Group.
Bramwell VH; Holdener EE; Siegenthaler P; Ten Bokkel Huinink W; Bruntsch U; Renard J; van Glabbeke M
Eur J Cancer Clin Oncol; 1984 Jun; 20(6):753-9. PubMed ID: 6547674
[TBL] [Abstract][Full Text] [Related]
32. Phase II evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with non-small cell lung cancer.
Casper ES; Gralla RJ; Kelsen DP; Natale RB; Sordillo P; Houghton A
Cancer Treat Rep; 1980; 64(2-3):345-7. PubMed ID: 6893294
[No Abstract] [Full Text] [Related]
33. AMSA and peptichemio in the treatment of advances metastatic breast cancer: a phase II study.
Buzdar AU; Legha SS; Hortobagyi GN; Powell KC; Blumenschein GR; Bodey GP
Am J Clin Oncol; 1982 Aug; 5(4):383-7. PubMed ID: 6896794
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
Coates AS; Bishop J; Mann GJ; Raghavan D
Eur J Cancer Clin Oncol; 1986 Jan; 22(1):97-100. PubMed ID: 3754214
[TBL] [Abstract][Full Text] [Related]
35. Phase II clinical trial of 4'-(9-acridinylamino) methanesulphon-m-anisidide (m-AMSA) in the treatment of advanced non-Hodgkin's lymphomas.
Abate G; Villari P; Comella P; D'Aprile M; Castello G; Silvestro P; Zarrilli D; Pergola M
Haematologica; 1985; 70(1):35-8. PubMed ID: 3924754
[No Abstract] [Full Text] [Related]
36. A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study.
Ettinger DS; Day R; Ferraro JA; Ruckdeschel JC; Woll JE; Creech RH; Vogl SE
Am J Clin Oncol; 1983 Apr; 6(2):167-70. PubMed ID: 6299093
[TBL] [Abstract][Full Text] [Related]
37. Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma.
Falkson G; MacIntyre JM; Schutt AJ; Coetzer B; Johnson LA; Simson IW; Douglass HO
J Clin Oncol; 1984 Jun; 2(6):581-4. PubMed ID: 6327926
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR
Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864
[TBL] [Abstract][Full Text] [Related]
39. m-AMSA: phase II trial in advanced lymphoma and leukemia.
Case DC
Am J Clin Oncol; 1984 Aug; 7(4):357-60. PubMed ID: 6588746
[TBL] [Abstract][Full Text] [Related]
40. Meta AMSA (m-AMSA) in patients with advanced ovarian carcinoma.
Kearsley JH; Page JP; Levi JA; Woods RL; Tattersall MH; Fox RM; Coates AS
Aust N Z J Obstet Gynaecol; 1982 May; 22(2):107-9. PubMed ID: 6958247
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
